SavedAdd your journal

Journals / Çocuk Dergisi / 2026 / Cilt: 10 Sayı: 1

Case report: Transient Myeloproliferative Disorder of Down Syndrome

Down Sendromunun Geçici Miyeloproliferatif Hastalığı: Vaka Sunumu

Mehmet Mutlu(Karadeniz Teknik Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Neonatoloji Bilim Dalı)
Erol Erduman(Karadeniz Teknik Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Hematoloji Bilim Dalı)
Yakup Aslan(Karadeniz Teknik Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Neonatoloji Bilim Dalı)
Pages
44–46
Publication Date
2010-01-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We emphasize the importance of the peripheral blood smear examination in newborns with DS, especially with leucocytosis or throm- bocytopenia in order to diagnose TMD-DS or acute leuke- mia

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Children with Down syndrome have a 10- to 20-fold incre- ased risk of developing leukemia.
📊
Key Findings & Data:Transient myeloprolife- rative disorder of Down syndrome TMD-DS occurs in 10-20 % of Down syndrome DS newborns.
💡
Conclusion & Impact:We emphasize the importance of the peripheral blood smear examination in newborns with DS, especially with leucocytosis or throm- bocytopenia in order to diagnose TMD-DS or acute leuke- mia
🔬Design:Makale
📍Scope:Comprehensive Sample
⚙️Variables:Down sendromu · geçici miyeloproliferatif hastalık · akut megakaryoblastik lösemi

Abstract

Children with Down syndrome have a 10- to 20-fold incre- ased risk of developing leukemia. Transient myeloprolife- rative disorder of Down syndrome TMD-DS occurs in 10-20 % of Down syndrome DS newborns. Acute mega- karyoblastic leukemia AML-M7 develops in approxima- tely 30 % of the cases with TMD-DS within the first three years of life. The distinctive finding of TMD-DS from acute leukemia is decreased percentage of the blasts in bone marrow compared to peripheral blood. In this case report, a newborn with TMD-DS is presented. We emphasize the importance of the peripheral blood smear examination in newborns with DS, especially with leucocytosis or throm- bocytopenia in order to diagnose TMD-DS or acute leuke- mia

Özet

Down sendromlu çocuklar 10 ila 20 kat artmış akut lösemi gelişme riskine sahiptir. Down sendromunun geçici miye- loproliferatif hastalığı DS-GMPH , Down sendromlu DS yenidoğanların % 10-20’sinde görülür. DS-GMPH’lu vakaların yaklaşık % 30’unda ilk üç yılda akut megakar- yoblastik lösemi AML-M7 gelişir. DS-GMPH’nın akut lösemiden ayrıcı bulgusu, kemik iliğindeki blast sayısının periferik kandakinden daha az olmasıdır. Bu vaka rapo- runda; DS-GMPH tanısı almış bir yenidoğan sunulmuştur. Down sendromlu yenidoğanlarda, özellikle de lökositozu veya trombositopenisi bulunanların periferik kan yayması incelemesinin, akut lösemi veya DS-GMPH yönünden önemi vurgulanmak istendi

🔖

Cite This Article

Mutlu, M., Erduman, E., Aslan, Y. (2010). Case report: Transient Myeloproliferative Disorder of Down Syndrome. Çocuk Dergisi, Cilt: 10 Sayı: 1, 44–46. https://doi.org/10.5222/j.child.2010.044

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down’s syndrome. Br J Haematol 2000; 110:512-24.
  2. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Ped Hemat Oncol 1992; 9:139-49.
  3. Tubergen DG, Bleyer A. The Leukemias. In: Kliegman RM, Berhmann RE, Jenson HB, Stanton BF, eds. Nelson Textbook of Pediatrics:. Nelson Texbook of Pediatrics. 18th ed. Philadelphia: Saunders Elsevier, 2007: 2116-22.
  4. Webb DKH. Optimizing therapy for myeloid disorders of Down syndrome. Br J Haematol 2005; 131:3-7.
  5. Brink DS. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. Adv Anat Pathol 2006; 13:256-62.
  6. Lorsbach RB. Megakaryoblastic disorders in children. Am J Clin Pathol 2004; 122:33-46.
  7. Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): a Children’s Oncology Group (COG) study POG-9481. Blood 2006; 107:4606-13.
  8. Hayashi Y, Eguchi M, Sugita K, et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down’s syndrome. Blood 1988; 72:15- 23.
  9. Zipursky A, Brown EJ, Christensen H, Doyle J. Transient myeloproliferative disorder (transient leukemia) and hematologic manifestations of Down syndrome. Clin Lab Med 1999; 19:157-67.
  10. Yagihashi N, Watanabe K, Yagihashi S. Transient abnormal myelopoiesis accompanied by hepatic fibrosis in two infants with Down syndrome. J Clin Pathol 1995; 48:973-5.
  11. Zipursky A, Brown E, Christensen H, Sutherland R, Doyle J. Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol 1997; 21:97-101.
  12. Lorsbach RB. Megakaryoblastic disorders in children. Am J Clin Pathol 2004; 122:33-46.
  13. Anuk D, Tarcan A, Alioglu B, et al. Hydrops fetalis in a neonate with down syndrome, transient myeloproliferative disorder and hepatic fibrosis. Fetal Pediatr Pathol 2007; 26:223-8.
  14. Al-Kasim F, Doyle JJ, Massey GV, Weinstein HJ, Zipursky A. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group study. J Pediatr Hematol Oncol 2002; 24:9-13.
  15. Wechsler J, Greene M, McDevitt MA, et al. Acquired muta- tions in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32:148-52.
  16. Crispino JD. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol 2005; 16:137-47.
  17. Sato T, Toki T, Kanezaki R, et al. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. Br J Haematol 2008; 141:681-8.